Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy.

@article{Tsai2012PneumocystisJP,
  title={Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy.},
  author={M-J Tsai and C-W Chou and F-C Lin and Shi-chuan Chang},
  journal={Lupus},
  year={2012},
  volume={21 8},
  pages={914-8}
}
Pneumocystis jiroveci pneumonia (PCP) is an uncommon but potentially life-threatening infection in immunocompromised patients with low blood T cells. Rituximab, a chimeric human/murine monoclonal antibody against the B cell-specific antigen CD20, has been increasingly used and appears to be effective in the treatment of autoimmune disorders, including systemic lupus erythematosus (SLE). PCP has been reported in some patients with autoimmune diseases or lymphoma subjected to rituximab treatment… CONTINUE READING
5 Citations
15 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 15 references

Offlabel use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

  • M Ramos-Casals, FJ Garcı́a-Hernández, E de Ramón
  • Clin Exp Rheumatol
  • 2010

Similar Papers

Loading similar papers…